Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM0JKZ6)

Drug Name

DD01 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Obesity	5B81	Phase 1	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucagon receptor (GCGR)	TT9O6WS	GLR_HUMAN	Agonist	[2]
Glucagon-like peptide 1 receptor (GLP1R)	TTVIMDE	GLP1R_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Glucagon-like peptide 1 receptor (GLP1R)	DTT	GLP1R	2	2.848	3.472	2.963
Glucagon receptor (GCGR)	DTT	GCGR	4.695	1.926	1.322	3.797

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Obesity

ICD Disease Classification

5B81

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Glucagon-like peptide 1 receptor (GLP1R)	DTT	GLP1R	1.25E-01	0.17	1.26
Glucagon receptor (GCGR)	DTT	GCGR	7.24E-02	-0.52	-0.92

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT04812262) A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DD01 in Overweight/Obese Subjects With T2DM and NAFLD. U.S.National Institutes of Health.
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight